IRIS
FERRO, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.743
EU - Europa 2.970
NA - Nord America 2.641
SA - Sud America 634
AF - Africa 129
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.130
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.487
SG - Singapore 2.455
RU - Federazione Russa 1.684
CN - Cina 1.184
BR - Brasile 513
VN - Vietnam 393
IT - Italia 379
HK - Hong Kong 315
DE - Germania 239
IN - India 138
GB - Regno Unito 132
FI - Finlandia 126
NL - Olanda 122
KR - Corea 85
CA - Canada 62
FR - Francia 60
MX - Messico 56
AR - Argentina 53
IE - Irlanda 43
CI - Costa d'Avorio 40
PL - Polonia 38
ZA - Sudafrica 37
BD - Bangladesh 35
AT - Austria 29
SE - Svezia 28
ID - Indonesia 23
UA - Ucraina 20
EC - Ecuador 18
TR - Turchia 17
ES - Italia 16
JP - Giappone 14
IQ - Iraq 12
PY - Paraguay 12
KE - Kenya 11
PK - Pakistan 11
LT - Lituania 10
UZ - Uzbekistan 10
CO - Colombia 9
PE - Perù 9
CZ - Repubblica Ceca 8
VE - Venezuela 8
AZ - Azerbaigian 7
CL - Cile 6
IL - Israele 6
AE - Emirati Arabi Uniti 5
AU - Australia 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
TN - Tunisia 5
BG - Bulgaria 4
CH - Svizzera 4
DZ - Algeria 4
IR - Iran 4
LC - Santa Lucia 4
NZ - Nuova Zelanda 4
PA - Panama 4
BB - Barbados 3
BE - Belgio 3
BO - Bolivia 3
EG - Egitto 3
JM - Giamaica 3
JO - Giordania 3
KG - Kirghizistan 3
MA - Marocco 3
NI - Nicaragua 3
NP - Nepal 3
RS - Serbia 3
TT - Trinidad e Tobago 3
AM - Armenia 2
BH - Bahrain 2
CR - Costa Rica 2
CV - Capo Verde 2
CW - ???statistics.table.value.countryCode.CW??? 2
CY - Cipro 2
ET - Etiopia 2
GA - Gabon 2
HN - Honduras 2
MK - Macedonia 2
NA - Namibia 2
PT - Portogallo 2
RO - Romania 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
UG - Uganda 2
UY - Uruguay 2
ZM - Zambia 2
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CD - Congo 1
CU - Cuba 1
GD - Grenada 1
GM - Gambi 1
GN - Guinea 1
GR - Grecia 1
Totale 11.100
Salva come PNG Salva come JPEG
Città #
Singapore 1.218
Hefei 469
Moscow 389
Ashburn 361
Beijing 322
Hong Kong 313
Chandler 202
Santa Clara 162
Naples 129
Los Angeles 127
Ho Chi Minh City 106
Munich 102
Amsterdam 100
Dong Ket 96
Kochi 87
Seoul 84
New York 72
Redondo Beach 60
Dallas 55
Hanoi 54
Turku 54
São Paulo 53
Millbury 44
Boston 42
Enfield 41
Buffalo 37
Des Moines 36
Mexico City 33
Seattle 33
Warsaw 32
Frankfurt am Main 30
Nuremberg 30
Princeton 30
San Jose 29
Nanjing 28
Orem 28
Lappeenranta 27
Brooklyn 26
Phoenix 26
Helsinki 25
Montreal 23
Denver 22
Johannesburg 22
Lawrence 22
London 22
Houston 21
Chicago 20
Düsseldorf 18
Napoli 18
The Dalles 18
Atlanta 17
Ottawa 17
Stockholm 17
Dublin 16
Washington 16
Milan 15
Wilmington 15
Casamassima 14
Ninh Bình 14
Poplar 14
Tokyo 14
Bari 12
Biên Hòa 12
Chennai 12
Da Nang 12
Rio de Janeiro 12
Vienna 12
Belo Horizonte 11
Brasília 11
Rome 11
San Francisco 11
Tianjin 11
Boardman 10
Dearborn 10
Querétaro 10
Buenos Aires 9
Changsha 9
Charlotte 9
Hebei 9
Nairobi 9
Thái Bình 9
Ankara 8
Bengaluru 8
Manchester 8
Tashkent 8
Baku 7
Campinas 7
Dhaka 7
Falkenstein 7
Haiphong 7
Jiaxing 7
Kronberg 7
Lauterbourg 7
Lima 7
Manaus 7
Phủ Lý 7
Pune 7
Toronto 7
Chengdu 6
Florence 6
Totale 5.913
Salva come PNG Salva come JPEG
Nome #
Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets 195
Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials 138
Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer 137
Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer 126
Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content. 125
Serum (-2)proPSA/freePSAratio, (-2)proPSA/freePSA density, prostate health index, and prostate health index density as clues to reveal postoperative clinically significant prostate cancer in men with prostate-specific antigen 2-10 ng/mL 124
Epigenetic signature: A new player as predictor of clinically significant prostate cancer (PCa) in patients on active surveillance (AS) 124
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer 123
Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients. 122
Reliability of Multiparametric Magnetic Resonance Imaging in Patients with a Previous Negative Biopsy: Comparison with Biopsy-Naïve Patients in the Detection of Clinically Significant Prostate Cancer 120
Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: Systematic review and meta-analysis 120
Modified glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical Cystectomy: A multicenter experience 120
Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis 120
Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers 119
Urinary Micro-RNAs As Biomarkers of Urological Cancers: A Systematic Review 118
New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index 118
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients 118
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis 117
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy 115
Biomarkers in localized prostate cancer 114
Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine 114
Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicentre study 114
Advances in Urinary Diversion: From Cutaneous Ureterostomy to Orthotopic Neobladder Reconstruction-A Comprehensive Review 113
The Impact of Meat Intake on Bladder Cancer Incidence: Is It Really a Relevant Risk? 112
The Role of Butirprost® as an Adjuvant in Enhancing the Effect of Antibiotics in Patients Affected by Chronic Bacterial Prostatitis: A Randomized Prospective Trial 112
Optimized Identification of High-Grade Prostate Cancer by Combining Different PSA Molecular Forms and PSA Density in a Deep Learning Model 112
Peri-Prostatic Adipocyte-Released TGFβ Enhances Prostate Cancer Cell Motility by Upregulation of Connective Tissue Growth Factor 111
Neutrophil, platelets, and eosinophil to lymphocyte ratios predict gleason score upgrading in low-risk prostate cancer patients 110
Subcellular Localization of uc.8+ as a Prognostic Biomarker in Bladder Cancer Tissue 110
Exploring the Multifactorial Landscape of Penile Cancer: A Comprehensive Analysis of Risk Factors 109
Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading 109
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non–muscle-invasive Bladder Cancer 109
Artificial Intelligence and Machine Learning in Prostate Cancer Patient Management-Current Trends and Future Perspectives 109
Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG 108
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States 107
Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol 107
Ablative Treatments for Small Renal Masses and Management of Recurrences: A Comprehensive Review 106
Soluble interleukin-6 receptor to interleukin-6 (sIL-6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy 106
Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance 106
Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance 106
Predicting pathological features at radical prostatectomy in patients with prostate cancer eligible for active surveillance by multiparametric magnetic resonance imaging 106
Predictors of residual T1 high grade on re-transurethral resection in a large multi-institutional cohort of patients with primary T1 high-grade/grade 3 bladder cancer 106
The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial 105
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study 104
High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study 102
Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF‐1 upregulation of TUBB2B beta‐tubulin isoform 102
Unlocking Precision Medicine: Liquid Biopsy Advancements in Renal Cancer Detection and Monitoring 101
The relationship between the history of PDE5-inhibitors assumption and melanoma: a systematic review 101
Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy 101
Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional database 100
The evolving landscape of renal surgery for complex renal masses (CRM): implications for oncologic and functional outcomes 100
Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma 100
Salvage radical prostatectomy after external beam radiation therapy: A systematic review of current approaches 99
Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor 99
Early and late post-procedural complications in different orthotopic neobladder surgical approaches: A systematic review 98
The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review 98
Robot-assisted Partial Nephrectomy: 5-yr Oncological Outcomes at a Single European Tertiary Cancer Center 98
Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone 98
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer 97
Management of the incidental adrenal mass, continued surveillance versus surgical excision: analysis of US claims data on contemporary socio-demographic predictors and perioperative outcomes 96
Outcomes and Techniques of Robotic-Assisted Partial Nephrectomy (RAPN) for Renal Hilar Masses: A Comprehensive Systematic Review 96
The emerging role of obesity, diet and lipid metabolism in prostate cancer 96
Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies 96
Radiomics in prostate cancer: an up-to-date review 95
Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review 94
New Cross-Talk Layer between Ultraconserved Non-Coding RNAs, MicroRNAs and Polycomb Protein YY1 in Bladder Cancer 94
Urologic malignancies: advances in the analysis and interpretation of clinical findings 94
Novel Key Ingredients in Urinary Tract Health-The Role of D-mannose, Chondroitin Sulphate, Hyaluronic Acid, and N-acetylcysteine in Urinary Tract Infections (Uroial PLUS®) 93
Which inflammatory marker, between systemic immune-inflammation index and neutrophil to eosinophil ratio, is associated with Peyronie's disease and are there any implications for a better understanding of its mechanisms? 93
The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy-naive patients, according to the localization of the lesion at the mpMRI: A single-center retrospective observational study 92
Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. 92
Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies 92
Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification 88
SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study 88
Circular RNAs: An emerging type of non-coding RNA and their potential implications in bladder cancer 86
Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy 86
A Neural Network Model Combining [-2]proPSA, freePSA, Total PSA, Cathepsin D, and Thrombospondin-1 Showed Increased Accuracy in the Identification of Clinically Significant Prostate Cancer 85
Patient Selection for Active Surveillance in the Multi-parametric Magnetic Resonance Imaging Era: A Step Forward in a Rapidly Evolving Field 85
The use of 68Ga prostate-specific membrane antigen PET-CT in prostate cancer: diagnostic challenges and therapeutic opportunities 85
Critical Appraisal of Leibovich 2018 and GRANT Models for Prediction of Cancer-Specific Survival in Non-Metastatic Chromophobe Renal Cell Carcinoma 84
Surgical blood loss during holmium laser enucleation of the prostate (HoLEP) is not affected by short-term pretreatment with dutasteride: a double-blind placebo-controlled trial on prostate vascularity 84
Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice 84
Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy 81
Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma 77
Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma 75
Upper Tract Urothelial Cancer: Guideline of Guidelines 75
Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality–free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients 74
Bladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term Analysis on Cardiovascular Disease and Cancer Incidence 73
The Correlation Between Body Mass Index and Prostate Volume: A Retrospective Analysis of Pre and Postoperative Measurements in Prostate Cancer Patients 73
Minimally invasive surgical therapies (MISTs) for lower urinary tract symptoms (LUTS): promise or panacea? 72
HoloLens® platform for healthcare professionals simulation training, teaching, and its urological applications: an up-to-date review 67
Liquid Biopsy: Current advancements in clinical practice for bladder cancer 67
FABP4-mediated ERK phosphorylation promotes renal cancer cell migration 67
Emerging Biomarkers in Bladder Cancer: Translating Molecular Advances into Precision Oncology 66
Antioxidant treatment for oligoasthenoteratozoospermia and varicocele: a DBPC trial to evaluate the impact of age and body mass index 66
Artificial intelligence and radiomics in evaluation of kidney lesions: a comprehensive literature review 65
Molecular Imaging Diagnosis of Renal Cancer Using 99mTc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques 63
Assessing the influence of smoking on inflammatory markers in bacillus Calmette Guérin response among bladder cancer patients: a novel machine-learning approach 62
Cancer Stem Cells in Renal Cell Carcinoma: Origins and Biomarkers 62
Radiogenomics in Renal Cancer Management-Current Evidence and Future Prospects 62
Totale 9.943
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.139
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.139
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021160 0 0 0 0 0 0 2 1 31 16 5 105
2021/2022338 9 4 2 0 6 3 6 12 30 39 108 119
2022/2023649 54 25 24 19 77 64 4 52 82 171 72 5
2023/2024551 10 75 100 39 29 56 10 72 7 8 90 55
2024/20253.821 135 148 21 55 168 136 352 211 334 475 1.487 299
2025/20265.494 854 911 961 939 1.382 402 45 0 0 0 0 0
Totale 11.323